|
1
|
de Groen PC, Gores GJ, LaRusso NF,
Gunderson LL and Nagorney DM: Biliary tract cancers. N Engl J Med.
341:1368–1378. 1999.
|
|
2
|
Shaib Y and El-Serag HB: The epidemiology
of cholangiocarcinoma. Semin Liver Dis. 24:115–125. 2004.
|
|
3
|
Khan SA, Emadossadaty S, Ladep NG, et al:
Rising trends in cholangiocarcinoma: is the ICD classification
system misleading us? J Hepatol. 56:848–854. 2012.
|
|
4
|
Nagino M, Ebata T, Yokoyama Y, et al:
Evolution of surgical treatment for perihilar cholangiocarcinoma: a
single-center 34-year review of 574 consecutive resections. Ann
Surg. 258:129–140. 2013.
|
|
5
|
Kitiyakara T and Chapman RW:
Chemoprevention and screening in primary sclerosing cholangitis.
Postgrad Med J. 84:228–237. 2008.
|
|
6
|
Wiencke K and Boberg KM: Current consensus
on the management of primary sclerosing cholangitis. Clin Res
Hepatol Gastroenterol. 35:786–791. 2011.
|
|
7
|
Beuers U: EASL Recognition Awardee 2009:
Prof. Raoul Poupon J Hepatol. 51:617–619. 2009.
|
|
8
|
Chapman R, Fevery J, Kalloo A, et al:
Diagnosis and management of primary sclerosing cholangitis.
Hepatology. 51:660–678. 2010.
|
|
9
|
Sano T, Shimada K, Sakamoto Y, Yamamoto J,
Yamasaki S and Kosuge T: One hundred two consecutive hepatobiliary
resections for perihilar cholangiocarcinoma with zero mortality.
Ann Surg. 244:240–247. 2006.
|
|
10
|
Shaib YH, Davila JA, Henderson L, McGlynn
KA and El-Serag HB: Endoscopic and surgical therapy for
intrahepatic cholangiocarcinoma in the united states: a
population-based study. J Clin Gastroenterol. 41:911–917. 2007.
|
|
11
|
Kozarek RA: Inflammation and
carcinogenesis of the biliary tract: update on endoscopic
treatment. Clin Gastroenterol Hepatol. 7(11 Suppl): S89–S94.
2009.
|
|
12
|
Blechacz B and Gores GJ:
Cholangiocarcinoma: advances in pathogenesis, diagnosis, and
treatment. Hepatology. 48:308–321. 2008.
|
|
13
|
Ustundag Y and Bayraktar Y:
Cholangiocarcinoma: a compact review of the literature. World J
Gastroenterol. 14:6458–6466. 2008.
|
|
14
|
Ramacciato G, Nigri G, Bellagamba R, et
al: Univariate and multivariate analysis of prognostic factors in
the surgical treatment of hilar cholangiocarcinoma. Am Surg.
76:1260–1268. 2010.
|
|
15
|
Nuzzo G, Giuliante F, Ardito F, et al:
Intrahepatic cholangiocarcinoma: prognostic factors after liver
resection. Updates Surg. 62:11–19. 2010.
|
|
16
|
Anderson CD, Pinson CW, Berlin J and Chari
RS: Diagnosis and treatment of cholangiocarcinoma. Oncologist.
9:43–57. 2004.
|
|
17
|
Cheung HH, Lee TL, Davis AJ, Taft DH,
Rennert OM and Chan WY: Genome-wide DNA methylation profiling
reveals novel epigenetically regulated genes and non-coding RNAs in
human testicular cancer. Br J Cancer. 102:419–427. 2010.
|
|
18
|
Jurkowska RZ, Jurkowski TP and Jeltsch A:
Structure and function of mammalian DNA methyltransferases.
Chembiochem. 12:206–222. 2011.
|
|
19
|
Oki Y, Aoki E and Issa JP: Decitabine -
bedside to bench. Crit Rev Oncol Hematol. 61:140–152. 2007.
|
|
20
|
Griffiths EA and Gore SD: DNA
methyltransferase and histone deacetylase inhibitors in the
treatment of myelodysplastic syndromes. Semin Hematol. 45:23–30.
2008.
|
|
21
|
Gravina GL, Festuccia C, Marampon F, et
al: Biological rationale for the use of DNA methyltransferase
inhibitors as new strategy for modulation of tumor response to
chemotherapy and radiation. Mol Cancer. 9:3052010.
|
|
22
|
Damaraju VL, Mowles D, Yao S, et al: Role
of human nucleoside transporters in the uptake and cytotoxicity of
azacitidine and decitabine. Nucleosides Nucleotides Nucleic Acids.
31:236–255. 2012.
|
|
23
|
Yang D, Torres CM, Bardhan K, Zimmerman M,
McGaha TL and Liu K: Decitabine and vorinostat cooperate to
sensitize colon carcinoma cells to Fas ligand-induced apoptosis in
vitro and tumor suppression in vivo. J Immunol. 188:4441–4449.
2012.
|
|
24
|
Schnekenburger M, Grandjenette C, Ghelfi
J, et al: Sustained exposure to the DNA demethylating agent,
2′-deoxy-5-azacytidine, leads to apoptotic cell death in chronic
myeloid leukemia by promoting differentiation, senescence, and
autophagy. Biochem Pharmacol. 81:364–378. 2011.
|
|
25
|
Chen MY, Liao WS, Lu Z, et al: Decitabine
and suberoylanilide hydroxamic acid (SAHA) inhibit growth of
ovarian cancer cell lines and xenografts while inducing expression
of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and
autophagy. Cancer. 117:4424–4438. 2011.
|
|
26
|
Yi TZ, Li J, Han X, et al: DNMT inhibitors
and HDAC inhibitors regulate E-cadherin and Bcl-2 expression in
endometrial carcinoma in vitro and in vivo. Chemotherapy. 58:19–29.
2012.
|
